Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ur-63325. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ur-63325 SCHEMBL29400818 | 1.00 | HRH4 (0.56) | HRH4HRH3 | |
| SCHEMBL604394 | 0.90 | HRH4 (0.70) | HRH4HRH3 | |
| SCHEMBL604570 | 0.84 | HRH3 (0.52) | HRH4HRH3 | |
| SCHEMBL602598 | 0.82 | HRH4 (0.65) | HRH4HRH3 | |
| SCHEMBL605963 | 0.82 | HRH4 (0.55) | HRH4HRH3 | |
| SCHEMBL27846388 | 0.81 | HRH4 (0.54) | HRH4HRH3 | |
| SCHEMBL602166 | 0.80 | HRH4 (0.80) | HRH4HRH3 | |
| SCHEMBL603127 | 0.80 | HRH3 (0.73) | HRH4HRH3 | |
| SCHEMBL604973 | 0.79 | HRH4 (0.58) | HRH4HRH3 | |
| SCHEMBL602424 | 0.78 | HRH4 (0.51) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111465602-B | Synthesis of 4-aminopyrimidine compounds | 帕劳制药有限公司 | 2023-05-23 | — | — | CN | claimed |
| EP-3697776-B1 | SYNTHESIS OF 4-AMINOPYRIMIDINE COMPOUNDS | PALAU PHARMA S L U (ES) | 2023-04-19 | — | — | EP | claimed |
| US-11180480-B2 | Synthesis of 4-aminopyrimidine compounds | SENSORION (FR) | 2021-11-23 | — | — | US | claimed |
| US-20200270228-A1 | SYNTHESIS OF 4-AMINOPYRIMIDINE COMPOUNDS | SENSORION (FR) | 2020-08-27 | — | — | US | claimed |
| EP-3697776-A1 | SYNTHESIS OF 4-AMINOPYRIMIDINE COMPOUNDS | Sensorion (FR) | 2020-08-26 | — | — | EP | claimed |
| CN-111465602-A | Synthesis of 4-aminopyrimidine compounds | 森索睿翁公司 | 2020-07-28 | — | — | CN | claimed |
| WO-2019076974-A1 | SYNTHESIS OF 4-AMINOPYRIMIDINE COMPOUNDS | SENSORION (FR) | 2019-04-25 | — | — | WO | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | claimed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | claimed |
| EP-2858647-B1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2018-05-23 | — | — | EP | claimed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | claimed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | claimed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | claimed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | claimed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | claimed |
| CN-101903385-B | 4-aminopyrimidine derivatives as histamine H4 receptor antagonists | PALAU PHARMA SA | 2013-11-06 | — | — | CN | claimed |
| US-8431580-B2 | 4-aminopyrimidine derivatives as histamine H4 receptor antagonists | PALAU PHARMA, S.A. (ES) | 2013-04-30 | — | — | US | claimed |
| CN-111465602-B | Synthesis of 4-aminopyrimidine compounds | 帕劳制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-2235012-A2 | 4-AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGOSNISTS | Palau Pharma, S.A. (ES) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080721-A2 | 4 -AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | PALAU PHARMA, S. A. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270228-A1 | SYNTHESIS OF 4-AMINOPYRIMIDINE COMPOUNDS | KDM5D, KDM5B, KDM4D | HRH4 2458/4885HRH3 3689/4885 |
| US-11180480-B2 | Synthesis of 4-aminopyrimidine compounds | KDM5D, KDM5B, KDM4D | HRH4 2325/4885HRH3 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.